Skip to main content
SpringerLink
Log in

Eczematous drug eruptions mostly manageable with emollients and corticosteroids

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Eczematous drug eruptions (EDEs) constitute up to 10% of cutaneous drug reactions, with biologics and some newer cancer treatments and antivirals regularly implicated. EDEs are generally mild, although bacterial superinfection is a risk. Drug withdrawal and rechallenge, where practical, is the gold standard diagnostic test. Dry skin, cutaneous immunomodulation and sometimes type IV hypersensitivity reactions underlie EDEs and treatments reflect this, with most patients responding to emollients and corticosteroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Blum AE, Burgin S. Eczematous drug eruptions. Am J Clin Dermatol. 2021;22(3):349–66.

    Article  Google Scholar 

  2. Soh JS, Yun WJ, Kim KJ, et al. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Inflamm Bowel Dis. 2015;21(4):832–9.

    Article  Google Scholar 

  3. Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology (Basel). 2009;219(3):263–7.

    Article  Google Scholar 

  4. Stoffel E, Maier H, Riedl E, et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol. 2018;178(5):1151–62.

    Article  CAS  Google Scholar 

  5. Caldarola G, Pirro F, Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20(6):665–72.

    Article  CAS  Google Scholar 

  6. Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254–63.

    Article  CAS  Google Scholar 

  7. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–68.

    Article  CAS  Google Scholar 

  8. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317–26.

    Article  Google Scholar 

  9. Balagula Y, Rosen A, Tan BH, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118(20):5078–83.

    Article  CAS  Google Scholar 

  10. Mufti A, Sachdeva M, Kim P, et al. A systematic review of eczematous eruptions in patients receiving biologic therapy. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.11.071.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Silverberg JI. Adult-onset atopic dermatitis. J Allergy Clin Immunol Pract. 2019;7(1):28–33.

    Article  Google Scholar 

  12. Sanz-Navarro J, Feal C, Dauden E. Treatment of human scabies with oral ivermectin: eczematous eruptions as a new non-reported adverse event. Actas Dermosifiliogr. 2017;108(7):643–9.

    Article  CAS  Google Scholar 

  13. Summers EM, Bingham CS, Dahle KW, et al. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149(7):814–8.

    Article  Google Scholar 

  14. Joly P, Benoit-Corven C, Baricault S, et al. Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study. J Invest Dermatol. 2007;127(12):2766–71.

    Article  CAS  Google Scholar 

  15. Nakamura M, Lee K, Singh R, et al. Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatol Treat. 2017;28(3):237–41.

    Article  CAS  Google Scholar 

  16. Vena GA, Cassano N, Coco V, et al. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol. 2013;35(3):447–50.

    Article  CAS  Google Scholar 

  17. Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019;74(1):14–27.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Caroline Fenton & Connie Kang

Authors
  1. Caroline Fenton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Connie Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie Kang.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

C. Fenton, a contracted employee of Adis International Ltd/Springer Nature, and C. Kang, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenton, C., Kang, C. Eczematous drug eruptions mostly manageable with emollients and corticosteroids. Drugs Ther Perspect 38, 13–18 (2022). https://doi.org/10.1007/s40267-021-00881-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-021-00881-8

Search

Navigation